NASDAQ$OFIX
Orthofix Medical Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Orthofix reported record Q4 2024 results driven by strong execution and focus on profitable growth opportunities.
Orthofix reported record fourth quarter net sales of $215.7 million, an increase of 8% compared to the fourth quarter of 2023. The company's net loss was $(29.1) million, with a non-GAAP adjusted EBITDA of $23.9 million.
- Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023
- U.S. Spine Fixation net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing accounts
- Record Bone Growth Therapies (BGT) net sales of $63.9 million, representing growth of 9% and BGT Fracture net sales growth of 10% compared to fourth quarter 2023
- Record Global Orthopedics net sales of $35.8 million, representing constant currency growth of 18% and U.S. Orthopedics net sales growth of 21% compared to fourth quarter 2023
Headline financials
Revenue & EPS history
Orthofix · Revenue · Quarterly
$216M
Revenue by segment
Orthofix · $83.1M total across 2 segments · Q3 2023
- Bone Growth Therapies$53.4M+14.8%64.3%
- Global Limb Reconstruction$29.7M+6.8%35.7%
Forward guidance
The Company is providing full-year 2025 guidance. Net sales expected to range between $818 million to $826 million, excluding sales from the discontinued M6 artificial disc product lines and including a negative impact from foreign currency of approximately $4 million. Non-GAAP adjusted EBITDA expected to be $82 million to $86 million. Positive free cash flow expected for full-year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6-C artificial cervical and M6-L artificial lumbar disc product lines.
Tailwinds
- Net sales expected to range between $818 million to $826 million, excluding sales from the discontinued M6 artificial disc product lines and including a negative impact from foreign currency of approximately $4 million
- The Company’s expected net sales represent implied constant currency growth of 6.5% year-over-year at the midpoint of the range.
- Non-GAAP adjusted EBITDA expected to be $82 million to $86 million.
- This range includes the anticipated impact from the discontinuation of the M6 product lines.
- Positive free cash flow expected for full-year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6-C artificial cervical and M6-L artificial lumbar disc product lines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.9%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-3.4%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+20.3%
Q2 2014
Best reaction
-18.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -2.8% | -13.8% | |
| Q4 2025 | -7.0% | -0.4% | -13.2% | |
| Q3 2025 | -7.4% | -6.8% | -1.0% | |
| Q1 2025 | -10.8% | -10.6% | -20.9% | |
| Q4 2024 | -3.5% | -4.2% | -11.0% | |
| Q3 2024 | +5.5% | +4.6% | +1.2% | |
| Q2 2024 | +13.8% | +10.8% | +16.7% | |
| Q1 2024 | +10.7% | +8.8% | +0.6% | |
| Q4 2023 | +8.1% | +7.1% | +8.6% | |
| Q3 2023 | -12.5% | -20.2% | -3.2% | |
| Q2 2023 | +9.9% | +7.6% | +1.3% | |
| Q1 2023 | +1.0% | -2.3% | +6.7% | |
| Q4 2022 | -7.7% | -13.2% | -15.5% | |
| Q3 2022 | -2.2% | +4.1% | +30.5% | |
| Q2 2022 | -6.6% | -8.8% | -20.9% | |
| Q1 2022 | -10.5% | -14.3% | -11.6% | |
| Q4 2021 | +4.0% | +3.5% | +0.4% | |
| Q3 2021 | -5.9% | -10.9% | -18.6% | |
| Q2 2021 | +8.9% | +4.1% | +12.4% | |
| Q1 2021 | +0.5% | -2.0% | -8.7% | |
| Q4 2020 | +0.6% | -0.5% | -7.3% | |
| Q3 2020 | +5.2% | +13.6% | +10.8% | |
| Q2 2020 | +4.5% | +4.6% | -13.4% | |
| Q1 2020 | -1.9% | -6.9% | +3.9% | |
| Q4 2019 | -18.5% | -21.5% | -40.9% | |
| Q3 2019 | -16.8% | -17.0% | -9.6% | |
| Q2 2019 | +0.1% | +2.6% | -5.5% | |
| Q1 2019 | -2.6% | -0.3% | -10.9% | |
| Q4 2018 | -8.5% | -10.0% | -14.8% | |
| Q3 2018 | +7.4% | +8.8% | +4.1% | |
| Q2 2018 | -15.1% | -11.9% | -12.1% | |
| Q1 2018 | -13.4% | -14.6% | -10.5% | |
| Q4 2017 | +6.4% | +4.6% | +8.4% | |
| Q3 2017 | +8.8% | +5.1% | +9.6% | |
| Q2 2017 | +9.9% | +6.8% | +12.3% | |
| Q1 2017 | +1.4% | +3.8% | +8.2% | |
| Q4 2016 | -6.1% | -4.8% | +2.6% | |
| Q3 2016 | -3.8% | -6.8% | -1.5% | |
| Q2 2016 | -10.4% | -10.5% | -4.8% | |
| Q1 2016 | +0.4% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | +14.4% | — | — | |
| Q2 2015 | +13.8% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | -10.8% | — | — | |
| Q3 2014 | +20.3% | — | — | |
| Q2 2014 | +20.3% | — | — | |
| Q1 2014 | +4.2% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +1.1% | — | — | |
| Q2 2013 | -0.8% | — | — | |
| Q1 2013 | -16.4% | — | — | |
| Q4 2012 | -4.9% | — | — | |
| Q3 2012 | -2.8% | — | — | |
| Q2 2012 | +4.5% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q1 2010 | -4.8% | — | — | |
| Q4 2011 | -4.8% | — | — | |
| Q4 2009 | -4.8% | — | — | |
| Q3 2010 | -7.4% | — | — | |
| Q3 2011 | -7.4% | — | — | |
| Q4 2010 | -9.5% | — | — | |
| Q2 2010 | -9.5% | — | — | |
| Q2 2011 | -9.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro